Carla Eugenia Matellán

Médico esp. en reumatología.

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Systemic lupus erythematosus is one autoimmune disease for which CAR-T cell therapies have shown substantial promise in clinical trials. Find out more about therapeutic advances for lupus in this comprehensive review
https://t.co/gBHwh9QxlS
https://t.co/rxrnJTS4DY

[Dr hanady manasfi @hanadymanasfi]

CTD-ILD
ACR/Chest Guidelines #immunosuppressives #antifibrotics

[Alberto Giraldo @alb_giraldo]

The 2025 update of EULAR recommendations for the management of #Behçet’s syndrome, recently published in Annals of the Rheumatic Diseases, include 5 overarching principles and 12 recommendations organised by organ involvement.

◦ Overarching principles stress the relapsing-remitting nature of the disease, individualised treatment based on activity and prognostic factors, a multidisciplinary approach, patient education, and shared decision-making.

◦ Key recommendations:
- Mucocutaneous and joint involvement: Colchicine is first-line; apremilast or TNFα inhibitors for refractory cases.
- Organ-threatening disease: Early aggressive therapy with glucocorticoids + immunosuppressives, with prompt use of monoclonal TNFα inhibitors encouraged for severe or life-threatening manifestations.

Of the 12 recommendations, 1 is entirely new, 7 were modified, and 4 had only wording changes.

*Hatemi G, Ramiro S, Ozguler Y, et al. EULAR recommendations for the management of Behçet’s syndrome: 2025 update. Ann Rheum Dis. Published online March 23, 2026.
🔗https://t.co/dVblStDVGn

[Sjögrens Forum @SjogrensForum]

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease - Deboo - Arthritis Care & Research - Wiley Online Library #sjogrens #sjogrensfoundation

https://t.co/kQ4Q6wU7bl

[The Lancet @TheLancet]

VEXAS syndrome is a newly discovered multisystemic disease affecting most organs.

A Review provides a comprehensive overview of VEXAS syndrome, including the disease's discovery, diagnosis, and treatment: https://t.co/2BPPLfwDD9

[Residente de Crítica @DailyUrgencias]

Diagnóstico y tratamiento de Lupus Eritematoso Sistémico by @JAMA_current #LES #LUPUS

Descarga: https://t.co/bQ6aRDzpco

[Rheuma Doc @LastManStand85]

EULAR 2025 Haemochromatosis arthropathy classification criteria #Rheumatology #MedTwitter

[Autoinmunes Medicina Interna Parc Taulí @autoinMI_tauli]

New EULAR/ACR classification criteria for Antisynthetase Syndrome

✅ Anti-ARS antibodies & ILD are top drivers
🧪 ANA, SSA, MSA testing crucial to apply/exclude criteria
🧠 Score ≥5.5 + anti-ARS = definite ASyS
⏩ most weighted items = anti-ARS , ILD, myositis
#EULAR2025

[vasculitides @vasculitides]

The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis https://t.co/pS5S1G363U

[Rheuma Doc @LastManStand85]

2025 EULAR Recommendations for #Lupus Nephritis
➡️ Kidney Biopsy Essential!
✅ Early combo therapy 💊💉 HCQ/GC + MMF + OBI/BEL or CNI
✅ Taper Steroid to 5mg OD by 6/12
✅ Non-immune Rx: SGLT2i if ongoing Proteinuria after 12/12
🚨Severe: High dose IV Steroid & Cyclo
#MedTwitter

[Gabriel Puche, MD/PhD @gabi_puchepalao]

🆕 Criterios de clasificación del síndrome
antifosfolipídico ACR🇺🇸/🇪🇺EULAR 2023

🔎Al menos 1 prueba anticuerpos
antifosfolípidos (aPL) + en los 3⃣ años posteriores al evento clínico, seguido de criterios ponderados aditivos

Acceso: https://t.co/jnTKdXYePZ

Dentro hilo 🧵🪡

[Gabriel Puche, MD/PhD @gabi_puchepalao]

⚡️RECOMENDACIONES MANEJO SÍNDROME ANTIFOSFOLÍPIDICO (EULAR 2019) ⚡️

👉 Profilaxis primaria
👉 Profilaxis secundaria
👉 Manejo pacientes embarazadas
👉 SAF catastrófico (CAPS)

Dentro hilo 🧵🪡

[Andreas Kronbichler @AKronbichler]

Please find our Editorial discussing key differences between pediatric and adult ANCA-GN in @bmj_rmdopen! https://t.co/5iLLpCsveJ
Together with @louise_oni and Dr. Barnini! Interesting aspects clearly highlighting huge differences ...

[Laurent ARNAUD @Lupusreference]

🚨 The #REGENCY phase 3 trial of #obinutuzumab in #Lupus #nephritis has just been published in the NEJM!!!
DOWNLOAD LINK: https://t.co/z6C0KElEls

[Dr.Mukesh , MD , DM @dr_immuno29]

🔍 **Emerging Insights into #HandOsteoarthritis Biomarkers:**
1. **Heterogeneous Joint Disease:** High prevalence, varied symptoms. 🔄
2. **Biomarkers Key Areas:**
- Cartilage health & degradation 🦴
- Bone remodeling
- Inflammation
- Adipokines affecting metabolism
- Miscellaneous markers 🧬
3. **BIPED Criteria:** None meet optimal classification yet.
4. **Future Focus:** Develop sensitive assays & standardized tools for global applicability in HOA treatments! 📈
🧪 **Conclusion:** More research is crucial for effective diagnostic tools & strategies!

📖 Read more: (https://t.co/DIUY083Q8M).

#Biomarkers #PrecisionMedicine #JointHealth #Rheumatology #MedTwitter #RheumTwitter

[Antoni Chan MD (Prof) @synovialjoints]

Treatment of rheumatologic complications (inflammatory arthritis, polymyalgia rheumatica and myositis/myalgia) from immune checkpoint inhibitors. Review by Cappelli LC et al

https://t.co/w4LRoe58BR

[Antoni Chan MD (Prof) @synovialjoints]

The pathophysiology of Axial Spondyloarthritis. A review by Bittar A et al https://t.co/gewUUIrpNv #axialspondyloarthritis

[ERM @Owner_X429]

https://t.co/WbfwbcakYU

[NDT @NDTsocial]

Light-chain (AL) amyloidosis for nephrologists—treatment standard

https://t.co/eeA04nZoQP

[Luis Caminal @caminalm]

Indian Rheumatology Association guidelines for the management of ANCA ... https://t.co/F3vA4CBuqy